SCHEMBL1745567

SCHEMBL1745567

COC(=O)CCc1ccc(OCc2cccc(-c3cccc(C(=O)O)c3)c2)cc1

nearest known ligand 0.63

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 11/20 0.63
FFAR4 Q5NUL3 2/20 0.63
AKR1B1 P15121 1/20 0.63
MRGPRX4 Q96LA9 6/20 0.60
TP53 P04637 2/20 0.60
PKM P14618 2/20 0.60
NFKB1 P19838 2/20 0.60
NFKB2 Q00653 2/20 0.60
RELA Q04206 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
RAB9A P51151 1/20 0.60
RXFP1 Q9HBX9 1/20 0.60
NR4A2 P43354 1/20 0.59
NR1H4 Q96RI1 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1744991 0.91 FFAR1 (0.77) FFAR1FFAR4AKR1B1
SCHEMBL1747355 0.88 FFAR1 (0.81) FFAR1FFAR4AKR1B1NR4A2
SCHEMBL1745049 0.87 FFAR1 (0.64) FFAR1FFAR4AKR1B1
SCHEMBL1746614 0.86 PPARD (0.65) FFAR1FFAR4AKR1B1
SCHEMBL1746636 0.86 FFAR1 (0.78) FFAR1FFAR4AKR1B1
SCHEMBL1746764 0.85 FFAR1 (0.61) FFAR1FFAR4AKR1B1
SCHEMBL1746501 0.85 FFAR1 (0.59) FFAR1FFAR4AKR1B1
SCHEMBL1745373 0.85 FFAR1 (0.61) FFAR1FFAR4AKR1B1NR4A2
SCHEMBL1747192 0.84 FFAR1 (0.78) FFAR1FFAR4AKR1B1
SCHEMBL1746619 0.84 FFAR1 (0.64) FFAR1FFAR4AKR1B1MRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR FFAR1 33/4885FFAR4 44/4885AKR1B1 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.